Zions Bacentive公司在2025年第4季将Novo Nordisk股份削减45.7%,因为制药商报告说,2026年2月3日收益丰厚,股本回报率达68.9%。 Zions Bancorporation cut its Novo Nordisk stake by 45.7% in Q4 2025, as the drugmaker reported strong earnings and a 68.9% return on equity on February 3, 2026.

2025年,Zions Bacentil公司在Novo Nordisk的股份减少了45.7%,目前持有36 059股,价值200万美元。 Zions Bancorporation reduced its stake in Novo Nordisk by 45.7% in Q4 2025, now holding 36,059 shares valued at $2 million. 丹麦制药商报告说,2026年2月3日的Q4收入丰厚,有10.1美元EPS和124.3亿美元的收入,超过估计数。 The Danish drugmaker reported strong Q4 earnings on February 3, 2026, with $1.01 EPS and $12.43 billion in revenue, exceeding estimates. 其股本回报率为68.91%,净利润率为33.03%。 It posted a 68.91% return on equity and 33.03% net margin. 股票交易额约为49.59美元,市场上限为2 214.43亿美元,前期P/E为14.29美元,红利收益率为5.41%。 The stock, trading around $49.59, has a market cap of $221.43 billion, a forward P/E of 14.29, and a 5.41% dividend yield. 分析师给它定了一个56.07美元目标的"等下" Analysts rate it a "Hold" with a $56.07 target.